TheraRadar
Data updated: Jul 17, 2026

PYLARIFY TRUVU (piflufolastat f-18) · APHELION

Approved 2026-03-06

PYLARIFY TRUVU is FDA-approved to treat 3 conditions (same as PYLARIFY).

Source: FDA Label
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-03-06
Patent Cliff
2037

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

APHELION
Active Ingredient: PIFLUFOLASTAT F-18

PYLARIFY TRUVU Approval History

Original
New Indication
New Form
Label Update
1 FDA actions from 2026 to 2026
Mar 2026 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer
Label

What PYLARIFY TRUVU Treats

3 indications

PYLARIFY TRUVU is approved for 3 conditions since its original approval in 2026. These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as PYLARIFY (same active ingredient).

Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PYLARIFY TRUVU FDA Label Details

Indications & Usage

FDA Label (PDF)

PYLARIFY TRUVU is FDA-approved to treat 3 conditions — same approved indications as PYLARIFY.

PYLARIFY TRUVU Patents & Exclusivity

Latest Patent: Jun 2037
Exclusivity: May 2026

Patents (6 active)

US11851407 Expires Jun 9, 2037
US10947197 Expires Jun 9, 2037
US8778305 Expires Sep 21, 2030
US12070513 Expires Jul 31, 2029
US9861713 Expires Jul 31, 2029
US8487129 Expires Nov 7, 2027

Exclusivity

NCE Until May 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for PYLARIFY TRUVU

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2037
  • • 6 active patents

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA220089 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.